Tradestie Institutional Equity Comparison Engine

OBIO vs BHST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

OBIO Overall Edge

OBIO Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Orchestra BioMed Holdings, Inc. Ordinary Shares (OBIO) driven by superior Momentum & Technical, Options & Structure while BHST counters with relative strength in Growth & Margin. Fundamentally, OBIO trades at N/M Forward P/E with -195.4% operating margin (-89.4% YoY revenue) versus BHST at N/M Forward P/E and -18.0% operating margin (+3.8% YoY). In options structure, OBIO sits in CONSOLIDATION (21st %ile IV; Dealer Gamma Walls on Pro) against BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
OBIO N/M vs BHST N/M Fwd P/E
Growth & Margin Winner BHST
Op Margin -195.4% vs -18.0% ยท YoY -89.4% vs +3.8%
Momentum & Technical Winner OBIO
1Y +41.2% vs -79.4% ยท 52W Pos 72% vs 6%
Options & Structure Winner OBIO
CONSOLIDATION (21st %ile IV) vs UNCLASSIFIED (N/A IV)
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.58
-6.0% 1D
Market Cap $550.9M
1M Return +20.29%
1Y Return +41.2%
Forward P/E N/M
Unified AI Score
41.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 64.0 Mom 40.0
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
1M Return -22.62%
1Y Return -79.4%
Forward P/E N/M
Unified AI Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: OBIO +41.2% BHST -79.4% Spread: +120.6 pp (OBIO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period OBIO Revenue BHST Revenue OBIO Op. Margin BHST Op. Margin Margin Edge
FY2022 $0M N/A -924.3% N/A OBIO
FY2023 $0M $10M -1866.2% -78.6% BHST
FY2024 $0M $30M -2437.5% -27.7% BHST
FY2025 $30M $30M -154.7% -16.2% BHST

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: OBIO (2) vs BHST (6)
Institutional Metric OBIO BHST Criterion Row Winner
Market Capitalization Scale $550.9M $29.9M Larger Scale OBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -89.4% +3.8% Higher Growth BHST
Operating Margin (TTM) Profitability -195.4% -18.0% Higher Margin BHST
Net Profit Margin Profitability -182.5% -31.2% Higher Margin BHST
Return on Equity (ROE) Capital Efficiency -182.3% -142.5% Higher ROE BHST
52-Week Range Position Momentum 72% ($3โ€“$8) 6% ($1โ€“$7) Stronger Trend OBIO
Beta / 30D Volatility Risk Regime 1.18ฮฒ ยท 88% Vol 0.25ฮฒ ยท 86% Vol Lower Realized Risk BHST
Unified Institutional Score Composite Signal 41.1 / 100 (SELL) 58.2 / 100 (HOLD) Higher Composite BHST

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full OBIO vs BHST Buy Guide
OBIO CONSOLIDATION
36d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 21st %ile
IV Regime Compressed (<25th %ile)
Live OBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BHST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither OBIO nor BHST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.